LSE:AZNPharmaceuticals
AstraZeneca Oncology Advances Raise Questions On Valuation And Future Growth
US FDA grants priority review to AstraZeneca (LSE:AZN) and Daiichi Sankyo's DATROWAY for treating triple negative breast cancer, supported by phase 3 data indicating strong patient outcomes.
AstraZeneca's Imfinzi based regimen receives a positive opinion in the EU for early stage and locally advanced gastric and gastroesophageal junction cancers.
These two regulatory steps highlight progress in AstraZeneca's oncology portfolio across the US and European markets.
AstraZeneca, listed in...